LAG-3/MHCII Blockade Bioassay, Propagation Model
Instructions for Use of Product(s)
Literature # TM571
The LAG-3/MHCII Blockade Bioassay is a bioluminescent cell-based assay that measures potency and stability of antibodies and other biologics designed to block the interaction of LAG-3 with its ligand, MHCII. LAG-3, also known as CD223, is an immune checkpoint receptor expressed on activated CD4+ and CD8+ T cells and natural killer (NK) cells. LAG-3 plays a critical role in regulating immune responses to tumor antigens and autoantigens. Engagement of LAG-3 by its best characterized ligand, major histocompatibility complex II (MHCII), inhibits TCR signaling, cytokine production and proliferation of activated T cells. Therapeutic antibodies designed to block the LAG-3/MHCII interaction show promising results in clinical trials for the treatment of a variety of cancers.
The LAG-3/MHCII Blockade Bioassay, Propagation Model (Cat.# JA1112) is a bioluminescent cell-based assay that measures the potency and stability of antibodies and biologics targeting LAG-3/MHCII and overcomes the limitations of existing assays. The LAG-3 Effector Cells and MHCII APC Cells are provided in a Cell Propagation Model (CPM) format, which includes cryopreserved cells that can be thawed, propagated and banked for long-term use (also offered in a thaw-and-use format; Cat.# JA1111, JA1115).
Printed in USA 7/19.